Experienced in Hepatic Venoocclusive Disease with Immunodeficiency

Dr. Tsiporah B. Shore

Oncology | Hematology | Transplant Surgery
Weill Medical College Of Cornell
520 E 70th St, Suite 341, 
New York, NY 
Offers Telehealth
39 Years of Experience
Experienced in Hepatic Venoocclusive Disease with Immunodeficiency
Weill Medical College Of Cornell
520 E 70th St, Suite 341, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tsiporah Shore is an Oncologist and a Hematologist in New York, New York. Dr. Shore has been practicing medicine for over 39 years and is rated as an Experienced provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 88 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 1 clinical trial in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Specialties
Oncology
Hematology
Transplant Surgery
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
520 E 70th St, Suite 341, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Anti-thymocyte globulin, Cyclophosphamide, Filgrastim, Mycophenolate mofetil, Plerixafor
Study Phase: Phase 2
Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Enrollment Status: Terminated
Publish Date: February 13, 2024
Intervention Type: Biological
Study Drugs: Haplo-identical cells, Umbilical cord blood unit
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Biological
Study Drugs: CPX-351, Fludarabine, Melphalan, Rabbit Anti-Human T-Lymphocyte Globulin, Haplo-Cord Stem Cell Transplantation
Study Phase: Phase 1
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
Enrollment Status: Completed
Publish Date: February 02, 2022
Intervention Type: Drug
Study Drug: Lu-177 J591
Study Phase: Phase 1
Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission
Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Radiation, Drug
Study Drugs: 5-Azacytidine, Fludarabine, Melphalan, Alemtuzumab
Study Phase: Phase 2
A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort
A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
Research Tissue Bank
Research Tissue Bank
Enrollment Status: Completed
Publish Date: July 05, 2019
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Enrollment Status: Terminated
Publish Date: March 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
View 13 Less Clinical Trials

88 Total Publications

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
Journal: Leukemia & lymphoma
Published: August 14, 2025
Similar Doctors
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Roni Tamari
Hematology Oncology | Hematology | Oncology
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Roni Tamari
Hematology Oncology | Hematology | Oncology

Mskcc Clinical Practice Plan

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Roni Tamari is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tamari is rated as a Distinguished provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Myelofibrosis, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Colonoscopy.

Sergio A. Giralt
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Sergio A. Giralt
Hematology Oncology | Hematology | Oncology
Distinguished in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Sergio A. Giralt
Hematology Oncology | Hematology | Oncology

Mskcc Clinical Practice Plan

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sergio Giralt is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Giralt is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Brian C. Shaffer
Hematology
Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Brian C. Shaffer
Hematology

Mskcc Clinical Practice Plan

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brian Shaffer is a Hematologist in New York, New York. Dr. Shaffer is rated as a Distinguished provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shore's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile